Cell and Gene Therapy: Rewriting the Future of Medicine – Technology Networks

Cell and gene therapies seek to correct the root cause of an illness at the molecular level. These game-changing medicines are reshaping how we address previously untreatable illnesses transforming peoples lives.

Cell and gene therapy represent overlapping fields of research with similar therapeutic goals developing a treatment that can correct the underlying cause of a disease, often a rare inherited condition that can be life-threatening or debilitating and has limited treatment options.

While these technologies were initially developed in the context of treating rare diseases caused by a single faulty gene, they have since evolved towards tackling more common diseases, says Professor Rafael J. Yez-Muoz, director of the Centre of Gene and Cell Therapy (CGCT) at Royal Holloway University of London.

A powerful example is the chimeric antigen receptor (CAR) T-cell therapies, which have been approved for treating certain blood cancers. The approach involves genetically modifying a patients T cells in the laboratory before reintroducing them into the body to fight their disease.

For the first time, we had an example of gene therapy to treat a more common disease demonstrating that the technology has wide applicability, enthuses Yez-Muoz.

To date, 24 cellular and gene therapy products have received approval from the US Food and Drug Administration (FDA) including life-changing treatments for patients with rare diseases, such as inherited forms of blindness and neuromuscular conditions. A variety of gene and cell-based therapies for both rare and common diseases are also currently in development across many therapeutic areas, offering hope for many more families in coming years.

This webinar will provide an introduction to the regulatory framework for cell and gene therapies and highlight the importance of chemistry, manufacturing and controls. Watch to learn about regulatory concerns, safety and quality testing throughout the product lifecycle and key acronyms and terminology.

Gene therapies seek to introduce specific DNA sequences into a patients body to treat, prevent or potentially cure a disease. This may involve the delivery of a functional gene into cells to replace a gene that is missing or causing a problem or other strategies using nucleic acid sequences (such as antisense oligonucleotides or short interfering RNAs [siRNAs]) to reduce, restore or modify gene expression. More recently, scientists are also developing genome-editing technologies that aim to change the cells DNA at precise locations to treat a specific disease.

The key step in successful gene therapy relies on the safe and efficient delivery of genetic material into the target cells, which is carried out by packaging it into a suitable delivery vehicle (or vector). Many current gene therapies employ modified viruses based on adenoviruses, adeno-associated viruses (AAV), and lentiviruses as vectors due to their intrinsic ability to enter cells. But non-viral delivery systems such as lipid nanoparticles (LNPs) have also been successfully employed to deliver RNA-based therapeutics into cells.

A big advantage of using viral vectors for gene delivery is they are longer lasting than non-viral systems, states Dr. Rajvinder Karda, lecturer in gene therapy at University College London. Many of the rare diseases were aiming to tackle are severe and we need to achieve long-term gene expression for these treatments to be effective.

While improved technological prowess empowers the development of CRISPR-edited therapies, supply-chain and manufacturing hurdles still pose significant barriers to clinical and commercialization timelines. Watch this webinar to learn more about the state of CRISPR cell and gene therapies, challenges in CRISPR therapy manufacturing and a next-generation manufacturing facility.

Viral-vector gene therapies are either administered directly into the patients body (in vivo), or cells harvested from a patient are instead modified in the laboratory (ex vivo) and then reintroduced back into the body. Major challenges for in vivo gene delivery approaches are with the safe and efficient targeting of the therapeutic to the target cells and overcoming any potential immune responses to the vectors.

As well as getting the genetic material into the affected cells, we also need to try and limit it reaching other cells as expressing a gene in a cell where its not normally active could cause problems, explains Dr. Gerry McLachlan, group leader at the Roslin Institute in Edinburgh.

For example, the liver was identified as a major site of toxicity for an AAV-based gene therapy approved for treating spinal muscular atrophy (SMA), a type of motor neuron disease that affects people from a very young age.

Unfortunately, these viruses are leaky as theyre also going to organs that dont need therapy meaning you can get these off-target effects, says Karda. Theres still work to be done to develop and refine these technologies to make them more cell- and organ-specific.

It is also important to ensure the gene is expressed at the right level in the affected cells too high and it may cause side effects and too little may render the treatment ineffective. In a recent major advancement in the field, scientists developed a dimmer switch system Xon that enables gene expression to be precisely controlled through exposure to an orally delivered small molecule drug. This novel system offers an unprecedented opportunity to refine and tailor the application of gene therapies in humans.

Download this whitepaper to discover an electroporation system that resulted in CAR transfection efficiencies as high as 70% in primary human T cells, can avoid the potential risks associated with viral transduction and is able to produce CAR T cells at a sufficient scale for clinical and therapeutic applications.

In 1989, a team of researchers identified the gene that causes the chronic, life-limiting inherited disease cystic fibrosis (CF) the cystic fibrosis transmembrane conductance regulator (CFTR). This was the first ever disease-causing gene to be discovered marking a major milestone in the field of human genetics. In people with CF, mutations in the CFTR gene can result in no CTFR protein, or the protein being made incorrectly or at insufficient levels all of which lead to a cascade of problems that affect the lungs and other organs.

Our team focuses on developing gene therapies to treat respiratory diseases in particular, were aiming to deliver the CTFR gene into lung cells to treat CF patients, says McLachlan.

The results of the UK Respiratory Gene Therapy Consortiums most recent clinical trial showed that an inhaled non-viral CTFR gene therapy formulation led to improvements in patient lung function.

While this was encouraging, the effects were modest and we need to develop a more potent delivery vehicle, explains McLachlan. Weve also been working on a viral-based gene therapy using a lentiviral vector to introduce a healthy copy of the CTFR gene into cells of the lung.

Kardas team focuses on developing novel gene therapy and gene-editing treatments for incurable genetic diseases affecting the central and peripheral nervous system and Yez-Muoz is aiming to develop new treatments for rare neurodegenerative diseases that affect children, including SMA and ataxia telangiectasia (AT).

But a significant barrier for academic researchers around the world is accessing the dedicated resources, facilities and expertise required to scale up and work towards the clinical development and eventually the commercial production of gene and cell therapies. These challenges will need to be addressed and overcome if these important advancements are to successfully deliver their potentially life-changing benefits to patients.

Download this app note to discover how electron activated dissociation can obtain in-depth structural characterization of singly charged, ionizable lipids and related impurities, decrease risk of missing critical low abundance impurities and increase confidence in product quality assessment.

After many decades of effort, the future of gene and cell therapies is incredibly promising. A flurry of recent successes has led to the approval of several life-changing treatments for patients and many more products are in development.

Its no longer just about hope, but now its a reality with a growing number of rare diseases that can be effectively treated with these therapies, describes Yez-Muoz. We now need to think about how we can scale up these technologies to address the thousands of rare diseases that exist and even within these diseases, people will have different mutations, which will complicate matters even further.

But as more of these gene and cell-based therapies are approved, there is a growing urgency to address the challenge of equitable access to these innovative treatments around the world.

Gene therapies have the dubious honor of being the most expensive treatments ever and this isnt sustainable in the longer term, says Yez-Muoz. Just imagine being a parent and knowing there is an effective therapy but your child cant access it that would be absolutely devastating.

See more here:
Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks

Growth in Cell and Gene Therapy Market – BioPharm International

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Cell and gene therapies (CGTs) offer significant advances in patient care by helping to treat or potentially cure a range of conditions that have been untouched by small molecule and biologic agents. Over the past two decades, more than 20 CGTs have been approved by FDA in the United States and many of these one-time treatments cost between US$375,00 and US$2 million a shot (1). Given the high financial outlay and patient expectations of these life-saving therapies, it is essential that manufacturers provide integrated services across the whole of the supply chain to ensure efficient biomanufacturing processes and seamless logistics to reduce barriers to uptake.

The following looks at the who, what, when, and why of biomanufacturing and logistics in CGTs in the bio/pharmaceutical industry in more detail.

According to market research, the global gene therapy market will reach US$9.0 billion by 2027 due to favorable reimbursement policies and guidelines, product approvals and fast-track designations, growing demand for chimeric antigen receptor (CAR) T cell-based gene therapies, and improvements in RNA, DNA, and oncolytic viral vectors (1).

In 2020, CGT manufacturers attracted approximately US$2.3 billion in investment funding (1). Key players in the CGT market include Amgen, Bristol-Myers Squibb Company, Dendreon, Gilead Sciences, Novartis, Organogenesis, Roche (Spark Therapeutics), Smith Nephew, and Vericel. In recent years, growth in the CGT market has fueled some high-profile mergers and acquisitions including bluebird bio/BioMarin, Celgene/Juno Therapeutics, Gilead Sciences/Kite, Novartis/AveXis and the CDMO CELLforCURE, Roche/Spark Therapeutics, and Smith & Nephew/Osiris Therapeutics.

Many bio/pharma companies are re-considering their commercialization strategies and have re-invested in R&D to standardize vector productions and purification, implement forward engineering techniques in cell therapies, and improve cryopreservation of cellular samples as well as exploring the development of off-the-shelf allogeneic cell solutions (2).

The successful development of CGTs has highlighted major bottlenecks in the manufacturing facilities, and at times, a shortage of raw materials (3). Pharma companies are now taking a close look at their internal capabilities and either investing in their own manufacturing facilities or outsourcing to contract development and manufacturing organizations (CDMOs) or contract manufacturing organizations (CMOs) to expand their manufacturing abilities (4). Recently, several CDMOsSamsung Biologics, Fujifilm Diosynth, Boehringer Ingelheim, and Lonzahave all expanded their biomanufacturing facilities to meet demand (5).

A major challenge for CGT manufacturers is the seamless delivery of advanced therapies. There is no room for error. If manufacturers cannot deliver the CGT therapy to the patient with ease, the efficacy of the product becomes obsolete. Many of these therapies are not off-the-shelf solutions and therefore require timely delivery and must be maintained at precise temperatures to remain viable. Thus, manufacturers must not only conform to regulations, but they must also put in place logistical processes and contingency plans to optimize tracking, packaging, cold storage, and transportation through the products journey. Time is of the essence, and several manufacturers have failed to meet patient demands, which have significant impacts on the applicability of these agents.

Several CAR T-cell therapies have now been approved; however, research indicates that a fifth of cancer patients who are eligible for CAR-T therapies pass away while waiting for a manufacturing slot (6). Initially, the manufacture of many of these autologous products took around a month, but certain agents can now be produced in fewer than two weeks (7). Companies are exploring new ways to reduce vein-to-vein time (collection and reinfusion) through the development of more advanced gene-transfer tools with CARs (such as transposon, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) among others, and the use of centralized organization with standardized apheresis centers (5). Others are exploring the use of the of allogeneic stem cells including Regen Biopharma, Escape Therapeutics, Lonza, Pluristem Therapeutics, and ViaCord (7).

Several gene therapies have also been approved, mainly in the treatment of rare disease (8). Many companies are evaluating novel gene therapy vectors to increase levels of gene expression/protein productions, reduce immunogenicity and improve durability including Astellas Gene Therapies, Bayer, ArrowHead Pharmaceuticals, Bayer, Bluebird Bio, Intellia Therapeutics, Kystal Biotech, MeiraGTx, Regenxbio, Roche, Rocket Pharmaceuticals, Sangamo Therapeutics, Vertex Pharmaceuticals, Verve Therapeutics, and Voyager Therapeutics (8).

While many biopharma companies have established their own in-house CGT good manufacturing practice (GMP) operation capabilities, others are looking to decentralize manufacturing and improve distribution by relying on external contracts with CDMOs and CMOs such as CELLforCURE, CCRM, Cell Therapies Pty Ltd (CTPL), Cellular Therapeutics Ltd (CTL), Eufets GmbH, Gravitas Biomanufacturing, Hitachi Chemical Advances Therapeutic Solutions, Lonza, MasTHerCell, MEDINET Co., Takara Bio, and XuXi PharmaTech (6, 9, 10).

The top 50 gene therapy start-up companies have attracted more than $11.6 billion in funds in recent years, with the top 10 companies generating US$5.3 billion in series A to D funding rounds (10). US-based Sana Biotechnology leads the field garnering US$700 million to develop scalable manufacturing for genetically engineered cells and its pipeline program, which include CAR-T cell-based therapies in oncology and CNS (Central Nervous System) disorders (11). In second place, Editas Medicine attracted $656.6 million to develop CRISPR nuclease gene editing technologies to develop gene therapies for rare disorders (12).

Overall, CGTs have attracted the pharma industrys attention as they provide an alternative route to target diseases that are poorly served by pharmaceutical and/or medical interventions, such as rare and orphan diseases. Private investors continue to pour money into this sector because a single shot has the potential to bring long-lasting clinical benefits to patients (13). In addition, regulators have approved several products and put in place fast track designation to speed up patient access to these life-saving medicines. Furthermore, healthcare providers have established reimbursement policies and manufacturers have negotiated value- and outcome-based contracts to reduce barriers to access to these premium priced products

On the downside, the manufacture of CGTs is labor intensive and expensive with manufacturing accounting for approximately 25% of operating expenses, plus there is still significant variation in the amount of product produced. On the medical side, many patients may not be suitable candidates for CGTs or not produce durable response due to pre-exposure to the viral vector, poor gene expression, and/or the development of immunogenicity due to pre-exposure to viral vectors. Those that can receive these therapies may suffer infusion site reactions, and unique adverse events such as cytokine release syndrome and neurological problems both of which can be fatal if not treated promptly (14).

Despite the considerable advances that have been made in the CGT field to date, there is still much work needed to enhance the durability of responses, increase biomanufacturing efficiencies and consistency and to implement a seamless supply chain that can ensure these agents are accessible, cost-effective, and a sustainable option to those in need.

Cleo Bern Hartley is a pharma consultant, former pharma analyst, and research scientist.

BioPharm InternationalVol. 35, No. 10October 2022Pages: 4951

When referring to this article, please cite it as C.B. Hartley, "Growth in Cell and Gene Therapy Market," BioPharm International 35 (10) 4951 (2022).

View post:
Growth in Cell and Gene Therapy Market - BioPharm International

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell…

ZUG, Switzerland and BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the Companys wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Szary Syndrome (MF/SS).

The RMAT designation is an important milestone for the CTX130 program that recognizes the transformative potential of our cell therapy in patients with T-cell lymphomas based upon encouraging clinical data to date, said Phuong Khanh (P.K.) Morrow, M.D., FACP, Chief Medical Officer of CRISPR Therapeutics. "We continue to work with a sense of urgency to bring our broad portfolio of allogeneic cell therapies to patients in need.

Established under the 21st Century Cures Act, RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising pipeline products, including genetic therapies. A regenerative medicine therapy is eligible for RMAT designation if it is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or therapy has the potential to address unmet medical needs for such disease or condition. Similar to Breakthrough Therapy designation, RMAT designation provides the benefits of intensive FDA guidance on efficient drug development, including the ability for early interactions with FDA to discuss surrogate or intermediate endpoints, potential ways to support accelerated approval and satisfy post-approval requirements, potential priority review of the biologics license application (BLA) and other opportunities to expedite development and review.

About CTX130 and COBALT TrialsCTX130, a wholly-owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR T investigational therapy targeting Cluster of Differentiation 70, or CD70, an antigen expressed on various solid tumors and hematologic malignancies. CTX130 is being investigated in two ongoing independent Phase 1 single-arm, multi-center, open-label clinical trials that are designed to assess the safety and efficacy of several dose levels of CTX130 in adult patients. The COBALT-LYM trial is evaluating the safety and efficacy of CTX130 for the treatment of relapsed or refractory T or B cell malignancies. The COBALT-RCC trial is evaluating the safety and efficacy of CTX130 for the treatment of relapsed or refractory renal cell carcinoma. CTX130 has received Orphan Drug and Regenerative Medicine Advanced Therapy designations from the FDA.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Forward-Looking StatementThis press release may contain a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements made by Dr. Morrow in this press release, as well as regarding CRISPR Therapeutics expectations about any or all of the following: (i) the status of clinical trials and discussions with regulatory authorities related to product candidates under development by CRISPR Therapeutics including, without limitation, expectations regarding the benefits of RMAT designation; and (ii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the potential for initial and preliminary data from any clinical trial and initial data from a limited number of patients not to be indicative of final trial results; the potential that clinical trial results may not be favorable; potential impacts due to the coronavirus pandemic, such as the timing and progress of clinical trials; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics product candidates; uncertainties regarding the intellectual property protection for CRISPR Therapeutics technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics most recent annual report on Form 10-K, quarterly report on Form 10-Q and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

CRISPR THERAPEUTICS standard character mark and design logo, CTX130 and COBALT are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel Eides+1-617-315-4493rachel.eides@crisprtx.com

View original post here:
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell...

Fighting Breast and Ovarian Cancer With a Lupus Antibody – Yale School of Medicine

Of the 1.5 million people living with lupus in the United States, 90% are women. This disease turns the bodys immune system against itself, potentially causing extreme pain, fatigue, difficulty thinking clearly, and cardiovascular disease.

Officially known as systemic lupus erythematosus, lupus is distinct among autoimmune diseases in the way circulating antibodies proteins that when functioning properly help to protect against disease react against DNA, the bodys instructions for building cells and passing traits from parents to children.

Drs. Peter M. Glazer and James Hansen discovered that one specific lupus antibody, known as 3E10, can penetrate cancer cells and make them sensitive to and killed by standard radiation and chemotherapy methods. Notably, this technique has shown significant effectiveness in killing cancer cells with DNA repair deficiencies, such as those with mutations in the tumor-suppressing BRCA2 gene that lead to higher rates of breast and ovarian cancer.

Now, nearly a decade since this discovery and with he help of a grant from Womens Health Research at Yale, researchers are close to advancing a treatment toward clinical trials while learning more about how this lupus antibody penetrates and kills cancer cells.

This discovery has unlocked promising new pathways for treatment of BRCA-related cancers that affect so many women around the world, said Glazer, the Robert E. Hunter Professor of Therapeutic Radiology, professor of genetics, and chair of the Department of Therapeutic Radiology. We have learned a great deal about how 3E10 interacts with DNA, and we continue to explore how this knowledge could be used to create therapies for other types of difficult-to-treat cancers.

Dr. Glazer and his colleague Dr. James E. Hansen, associate professor of therapeutic radiology, licensed the rights for their antibody discovery to a company, Patrys, Ltd., that has validated the work and developed 3E10 as a cancer therapy for human use. An earlier human study in Switzerland attempting to use 3E10 as a vaccine for lupus had already demonstrated that it is nontoxic. Phase 1 clinical trials could begin as early as next year, Dr. Glazer said, likely for patients with cancers related to mutations of BRCA1/2 genes or of another tumor suppressing gene known as PTEN.

This is very promising, Glazer said. I think it will be important to identify the right subgroup of patients for which this is most effective.

After publishing the results, Dr. Glazer and his colleagues leveraged the data to obtain a pair of large multiyear grants from the National Institutes of Health. With this funding and the help of Yale graduate student Audrey Turchick, the team has discovered that inside a cancer cell, 3E10 sticks to a DNA repair protein called RAD51. This causes the lethality for cancer cells that are deficient in BRCA1 and BRCA2 genes by preventing the cells from conducting the routine DNA repair necessary to sustain themselves.

With ongoing funding from the NIH, Dr. Glazers team, including structural biologist Dr. Franziska Bleichert, is building on these findings to enhance the anti-cancer potency of 3E10 and develop therapeutic strategies by identifying ways for the antibody to stick more strongly to RAD51.

In addition, an MD/PhD student in the lab, Elias Quijano, helped identify the capacity of 3E10 to bind with RNA a type of molecule used to carry out DNA instructions and carry RNA into a cancer cell, potentially with instructions that can kill the cell. Quijano and Drs. Glazer, Stephen Squinto, and Bruce Turner co-founded Gennao Bio, a company seeking to develop this method of cancer-fighting therapy.

This was an unexpected discovery that turns out may be very useful, Glazer said. We have some data showing the efficacy of this method against tumors in a laboratory model. It is a versatile platform, because it can deliver different types of RNA in a similar way to how the COVID-19 mRNA vaccines work.

The research continues, thanks in large part to the investment WHRY made so many years ago.

I think that type of funding is extremely valuable, Glazer said of his WHRY grant. It allowed us to do the sets of exploratory experiments we needed to do to demonstrate our approach was viable and get the larger grants. We showed this is feasible, this is promising.

Original post:
Fighting Breast and Ovarian Cancer With a Lupus Antibody - Yale School of Medicine

Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as…

SAN FRANCISCO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, todayannounced that the California Institute for Regenerative Medicine (CIRM) has awarded Excision a $6.85 million grant to support the clinical development of the EBT-101 program for human immunodeficiency virus type 1 (HIV-1).

Daniel Dornbusch, Chief Executive Officer of Excision, commented, We are honored that CIRM has recognized the potential value of the EBT-101 program and our dual-guide RNA CRISPR approach to developing curative therapies for HIV-1 as well as other serious viral diseases with significant unmet needs. The CIRM grant provides further validation for the EBT-101 clinical trial, which is the first ever to evaluate an in vivo CRISPR-based therapy in an infectious disease. The grant will provide Excision with important funding to advance the trial and potentially demonstrate the safety and efficacy of removing viral DNA from people affected by the HIV pandemic.

Excision recently reported the first participant in the EBT-101 Phase 1/2 clinical trial was dosed in July 2022, with initial findings indicating the therapeutic has been well tolerated to-date. The participant continues to be monitored for safety and is expected to qualify for analytical treatment interruption (ATI) of their background anti-retroviral therapy (ART) in an evaluation of a potential cure.

To date only a handful of people have been cured of HIV/AIDS, so this proposal of using gene editing to eliminate the virus could be transformative, says Maria T. Millan, MD, President and CEO of CIRM. In California alone there are almost 140,000 people living with HIV. HIV infection continues to disproportionately impact marginalized populations, many of whom are unable to access the medications that keep the virus under control. A functional cure for HIV would have an enormous impact on these communities, and others around the world.

About EBT-101EBT-101 is a unique, in vivo CRISPR-based therapeutic designed to cure HIV infections after a single intravenous infusion. EBT-101 employs an adeno-associated virus (AAV) to deliver CRISPR-Cas9 and dual guide RNAs, enabling a multiplex editing approach that simultaneously targets three distinct sites within the HIV genome. This allows for the excision of large portions of the HIV genome, thereby minimizing potential viral escape.

About the EBT-101 Clinical ProgramThe EBT-101 Phase 1/2 trial is an open-label, multi-center single ascending dose study designed to evaluate the safety, tolerability and preliminary efficacy of EBT-101 in approximately nine participants with HIV-1 who are suppressed on antiretroviral therapy. The clinical program is supported by preclinical studies that included positive long-term non-human primate safety data and efficacy data in humanized mice showing the potential to cure HIV when treated with EBT-101. The primary objective of the trial is to assess the safety and tolerability of a single dose of EBT-101 in study participants with undetectable viral load on antiretroviral therapy (ART). Biodistribution, pharmacodynamic, and efficacy assessments will also be conducted. All participants will be assessed for eligibility for an analytical treatment interruption (ATI) of their background ART at Week 12 post EBT-101 administration. Following the initial 48-week follow up period, all participants will be enrolled into a long-term follow up protocol. For more information, see ClinicalTrials.gov identifiers NCT05144386 (Phase 1/2 trial) and NCT05143307 (long-term follow up protocol).

About CIRMAt CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission.To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of todays most promising stem cell technologies.With $5.5 billion in funding and more than 150 active stem cell programs in our portfolio, CIRM is one of the worlds largest institutions dedicated to helping people by bringing the future of cellular medicine closer to reality. For more information go towww.cirm.ca.gov.

About Excision BioTherapeutics, Inc.Excision BioTherapeutics, Inc. is a clinical-stage biotechnology company developing CRISPR-based therapiesas potentialcures for viral infectious diseases. EBT-101, the Companys lead program, is anin vivoCRISPR-based therapeutic designed to cure HIV infections after a single intravenous infusion. Excisions pipeline unites next-generation CRISPR nucleases with a novel gene editing approach to develop curative therapies for Herpes Virus, JC Virus,which causes PML, and Hepatitis Bvirus. Excisions foundational technologies were developedin the laboratories of Dr. KamelKhaliliat Temple University andDr. JenniferDoudnaatthe University of California, Berkeley.For more information, please visitwww.excision.bio.

Contact:InvestorsJohn Fraunces - LifeSci Advisors917-355-2395jfraunces@lifesciadvisors.com

MediaRobert Flamm, Ph.D.Burns McClellan, Inc.212-213-0006 ext. 364rflamm@burnsmc.com

Link:
Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as...

The surprising link between circadian disruption and cancer may have to do with temperature – EurekAlert

image:For mice placed in chronic jet lag (CJL) conditions, they showed a 68% increase in tumor burden when compared to mice placed in 12 hours of light, 12 hours of darkness (12:12 LD). view more

Credit: Scripps Research

LA JOLLA, CADisruptions in circadian rhythmthe ways that our bodies change in response to the 24-hour light and dark cyclehave been linked to many different diseases, including cancer. The connection between the two has been poorly understood, even though shift workers and others with irregular schedules experience these disruptions regularly. But a new discovery from Scripps Research is helping answer what may be behind this correlation.

Published in Science Advances on September 28, 2022, the findings highlight that chronic circadian disruption significantly increased lung cancer growth in animal models. By identifying the genes implicated, the researchers are illuminating the mysterious link between our sleeping patterns and disease, which could help inform everything from developing more targeted cancer treatments to better monitoring high-risk groups.

There has always been a lot of evidence that shift workers and others with disrupted sleep schedules have higher rates of cancer, and our mission for this study was to figure out why, says senior author Katja Lamia, PhD, associate professor in the Department of Molecular Medicine.

To answer this question, the scientists used a mouse model with expressed KRAS the most commonly mutated gene in lung cancer. Half of the mice were housed in a normal light cycle, meaning 12 hours of light and 12 hours of darkness. The other half were housed in a light cycle meant to resemble that of shift workers, where the light hours were moved earlier by eight hours every two or three days.

The findings aligned with what the researchers initially thought: mice that were exposed to the irregular, shifting light patterns had an increased tumor burden of 68%.

But when they used RNA sequencing to determine the different genes involved in the cancer growth, they were surprised that a collection in the heat shock factor 1 (HSF1) family of proteins was the main culprit.

This is not the mechanism we were expecting to find here. HSF1 has been shown to increase rates of tumor formation in several different models of cancer, but it has never been linked to circadian disruption before, Lamia says.

HSF1 genes are responsible for making sure proteins are still made correctly even when a cell is under extreme stressin this case, when it experiences changes in temperature. The team suspects that HSF1 activity is increased in response to circadian disruption because changes in our sleep cycles disturb the daily rhythms of our bodies temperature.

Normally, our body temperature changes by one or two degrees while were sleeping. If shift workers dont experience that normal drop, it could interfere with how the HSF1 pathway normally operatesand ultimately lead to more dysregulation in the body, Lamia adds. She believes cancer cells may exploit the HSF1 pathway to their own benefit and create mutant, misfolded proteins, but says more research is needed in this area.

These findings help shape not only our understanding of how circadian rhythms impact cancer, but also potentially a preventative way of protecting more vulnerable groups who are at risk. By non-invasive monitoring of body temperature, it may be possible to optimize shift workers schedules and even halt this type of dysregulation that can lead to cancer.

With these discoveries in hand, the scientists are now evaluating if HSF1 signaling is required to increase tumor burden and isnt solely just a correlation.

Now that we know theres a molecular link between HSF1, circadian disruption and tumor growth, its our job to determine how theyre all connected, Lamia says.

In addition to Lamia, authors of the study, Circadian disruption enhances HSF1 signaling and tumorigenesis in Kras-driven lung cancer, include Marie Pariollaud, Lara H. Ibrahim, Emanuel Irizarry, Rebecca M. Mello, Alanna B. Chan, Michael J. Bollong and R. Luke Wiseman of Scripps Research; Brian J. Altman of University of Rochester Medical Center; and Reuben J. Shaw of Salk Institute.

Funding for this research was provided by the National Institutes of Health grant CA211187 (KAL), Brown Foundation for Cancer Research (KAL), National Institutes of Health grant DK107604 (RLW), National Institutes of Health grant R00CA204593 (BJA) and National Science Foundation/DBI-1759544 (EI).

About Scripps Research

Scripps Research is an independent, nonprofit biomedical institute ranked the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more atwww.scripps.edu.

Circadian disruption enhances HSF1 signaling and tumorigenesis in Kras-driven lung cancer

28-Sep-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Originally posted here:
The surprising link between circadian disruption and cancer may have to do with temperature - EurekAlert

Pfizer and Sangamo Therapeutics reopen recruitment for haemophilia A gene therapy trial – PMLiVE

Pfizer and Sangamo Therapeutics have reopened the recruitment of their phase 3 study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe haemophilia A, the companies announced.

The reopening comes after the two partners voluntarily paused the trial in November 2021 after patients treated with the therapy experienced blood clotting protein Factor VIII activity greater than 150%, raising concerns that they may be at increased risk of harmful clotting events.

The US Food and Drug Administration (FDA) subsequently placed a clinical hold on the trial, before lifting it in March this year. However, the partners kept the voluntary pause in place while working to meet all necessary conditions, including approval of updated trial protocols by regulatory authorities.

People living with haemophilia A lack sufficient functioning Factor VIII protein to help their blood clot. The condition occurs in around one in 5,000 male births annually, and more rarely in females. People with haemophilia can experience bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhages.

The phase 3 AFFINE study is an open-label, multicentre, single arm study to evaluate the efficacy and safety of a single infusion of giroctocogene fitelparvovec in more than 60 adult male participants, aged 18-64 years, with moderately severe to severe haemophilia A.

Eligible study participants will have completed at least six months of routine FVIII prophylaxis therapy during the lead-in phase 3 study in order to collect pretreatment data for efficacy and selected safety parameters, the companies stated.

The primary endpoint in AFFINE is the impact of giroctocogene fitelparvovec on annualised bleeding rate (ABR) after 15 months of follow-up. This will be compared to ABR on prior FVIII prophylaxis replacement therapy.

The secondary endpoints include FVIII activity level after the onset of steady state and after 15 months following infusion of giroctocogene fitelparvovec.

Trial sites will begin to resume enrolment this month, with dosing expected to resume in October and all trial sites anticipated to be active by the end of 2022, the companies outlined.

Giroctocogene fitelparvovec has been granted Orphan Drug, Fast Track and regenerative medicine advanced therapy designations by the FDA, as well as Orphan Medicinal Product designation by the European Medicines Agency.

View post:
Pfizer and Sangamo Therapeutics reopen recruitment for haemophilia A gene therapy trial - PMLiVE

At Columbia, Integrative Therapy for Children with Cancer Is Mainstream – Columbia University Irving Medical Center

Research suggests that when conventional medicine and integrative health treatments are practiced in tandem, cancer patients win. The multidisciplinary team at Columbias Center for Comprehensive Wellness puts that science into practice. The center offers treatments such as acupuncture and massage to support children with cancer and cancer patients of all ages during their treatment with chemotherapy and radiation.

Theres more evidence now than ever before that integrative treatment, as a support to essential conventional care, is a safe, effective approach to oncology care, says Elena J. Ladas, PhD, RD, the center's co-director. Integrative treatment, in combination with conventional medicine, gives patients the best quality of life.

Integrative health, also known as integrative medicine, is an approach to health care once referred to as alternative. In recent years, scientific research helped move such treatments as massage, acupuncture, nutrition, and exercise counseling into the mainstream.

One of the center's early studies found that treatment with milk thistle, a hepatoprotectant, can reduce toxic effects of chemotherapy on the liver. (Hepato means liver). Several studiesfound that acupuncture is an effective treatment for pain and chemotherapy-related nausea vomiting. The center's researchers also found acupuncture is safe among patients with severe immunosuppression or low platelet counts due to the cancer treatments.

Health professionals like Ladas and her team see the benefits of partnering different forms of medicinelike offering acupuncture alongside chemotherapyto best benefit patients. It's a benefit patients recognize: More than 80% of Columbias pediatric oncology patients take advantage of the integrative care. And they all come back for more, says Ladas, even when theyre off cancer therapy.

Our patients report integrative therapies help them with a variety of side effects related to cancer treatment," she says, such as pain, anxiety, insomnia, neuropathy, constipation, nausea/vomiting, and even excessive weight gain secondary to prolonged exposure to steroids.

Because of private donations, patients receive treatment for free. Its vital to the programs success, says Ladas, noting the economic diversity of patients. If these services werent free, people simply would not get them. This program brings wellness to all patients, irrespective of their ability to obtain or pay for integrative services. We view it as health equity; everyone should have the chance for as good a quality of life as possible while enduring treatment for cancer.

The center created the first integrative health program for children with cancer, a natural fit for Columbias Center for Comprehensive Wellness, because multidisciplinary careusing every available resourceis how most pediatric oncologists operate to lessen the pain experienced by their patients. (The survival rate for the most common pediatric cancers exceeds 80%.)

Our patients receive care in a soothing and welcoming atmosphere; they even sometimes look forward to coming in for treatment, says Luca Szalontay, MD, a pediatric hematologist-oncologist at Columbia University Vagelos College of Physicians and Surgeons. Seeing their loved one relax puts caretakers at ease, too, and allows doctors to focus on medical needs. The result is an unmistakably palpable change in the well-being of patients, their caretakers, and our medical workers, says Szalontay. Everyone wins.

At Columbia, integrative health professionals are a part of the patients comprehensive care team. Integrative health professionals attend medical rounds with physicians and nurses and make clinical recommendations in medical charts. Everyone in contact with a patient shares knowledge and updateseach aware of what another is doing.

The treatments used by Columbias Center for Comprehensive Wellness are based on the latest scientific research, and the center is also a leader in conducting scientific research about integrative treatments. The field has really come around, says Ladas. Its advanced, but we have a long way to go.

Current research projects at the center include studies on:

Visit link:
At Columbia, Integrative Therapy for Children with Cancer Is Mainstream - Columbia University Irving Medical Center

Calm App Review 2022: A Meditation App That’s Worth The Cost | mindbodygreen – mindbodygreen

While there are a good number of meditation apps on the market, Calm feels a bit different from the rest. From its neuroscience-inspired origins, light use of pop culture, and polished aesthetic, Calm feels like the cool spiritual uncle you want to hang out with.

The Calm app was founded in 2012 by Alex Tew and Michael Acton Smith. According to an Inc. report, the origin story of the app starts with Smith's bout of burnout and a big dose of skepticism around the "woo-woo" of meditation. But after cultivating his own mindfulness practice and reading more about the neuroscience behind meditation, Smith was convinced it was the right focus for his next business venture. Over the years, Calm's popularity has grown, snagging Apple's "App of the Year" in 2017. With over 4 million users, Calm continues to receive high praise on The App Store (4.8 stars) and Google Play Store (4.4 stars).

In general, accessing meditation and mindfulness through an app is way more convenient than researching a meditation studio, making your way there, sitting for 30 to 60 minutes, and making your way back home. If your goal is to make meditation and mindfulness a daily habit, using an app lowers the barrier, making your mindfulness practice as convenient as possible. With Calm, you simply sit wherever you are, open the app, and select a Calm meditation.

Read this article:
Calm App Review 2022: A Meditation App That's Worth The Cost | mindbodygreen - mindbodygreen

Allopathy-AYUSH Fusion: All Medical Colleges To Have Dept of Integrative Medicine Research | TheHealthSi – TheHealthSite

There is a possibility that MBBS students could pursue a week-long course in AYUSH systems of medicine

Written by Kashish Sharma | Published : September 27, 2022 2:08 PM IST

The National Medical Commission (NMC) has made it compulsory for all medical colleges to have a 'Department of Integrative Medicine Research'. The decision has been taken in an attempt to integrate modern medicine (called allopathy) with other medical schools that come under AYUSH.

The decision came after the first joint meeting of the National Medical Commission (NMC) with representatives of the National Commission for Homeopathy (NCH) and the National Commission for Indian Systems of Medicine (NCISM). A Kannur- based ophthalmologist Dr K.V Babu obtained the information on the meeting after filing an RTI inquiry.

As per the reports, discussions in the meeting were held on finding the best scientific methods of integrating all the schools of medicine to promote the development of all three sectors, help people receive integrated treatment, and to make medical students gain awareness and respect for other schools of medicine.

Among the possible changes, few are expected to affect the MBBS curriculum such as integrating Yoga as an essential practice for all students. Also, there is a possibility that MBBS students could pursue a week-long course in AYUSH systems of medicine.

In 2020, the government enacted the National Commission for Indian System of Medicine Act, 2020 and the National Commission for Homoeopathy Act, 2020 which allowed the medical practitioners of other medical schools like Ayurveda, Homeopathy to hold office in the capacity of a surgeon and practice modern medicine. They have been allowed to perform 39 general surgery procedures and 19 other procedures such as excisions of benign tumours, nasal, cataract surgeries and other procedures after they complete their post-graduation in the field. The provisions have been introduced by the government that aims to inaugurate an integrated system of medicine in India to be fully in function by 2030.

Recently, the Supreme Court has sought a response from the central government on a PIL challenging the laws that allow AYUSH practitioners to prescribe allopathic medicines and conduct surgeries. The PIL has alleged that the decision can endanger the lives of the public if not thought out carefully. The petitioners have argued that the decision would allow non-scientific, unproven methods of medicine to be applied to the public at large. The petitioners have however acknowledged the intent behind the decision to overcome the shortage of doctors by merging the alternative schools of medicine but they have admittedly called it a shortcut. Also, there have been concerns like the new laws would allow the practitioners of alternative medicines to use prefixes like 'Dr.' and 'surgeon' which might confuse people, especially in low awareness areas.

Follow us on

Here is the original post:
Allopathy-AYUSH Fusion: All Medical Colleges To Have Dept of Integrative Medicine Research | TheHealthSi - TheHealthSite

Top 5 ways to find joy in working out – Hindustan Times

Regular exercising is difficult. Perhaps not for those who love it or are in charge of it, but therein lies the issue. Exercise advocates are typically those who are most committed to it. The joyful movement places an emphasis on enjoying your physical movements. It is well recognised that exercise has numerous positive effects on both physical and mental health, and by putting an emphasis on enjoyment, you are more likely to move your body frequently. The choice is a factor in joyful movement. Exercises frequently appear to be required: they are carried out to burn off meals and to punish your body in order to achieve an ideal physique. The benefits of rest, your right to it, and your freedom to participate in it or not are all acknowledged by joyful movement. (Also read: Yoga for joy: 5 poses to promote happy hormones, beat stress )

Dr. Katie Takayasu, Integrative Medicine Doctor and Wellness Coach, suggested the top five ways to find joy in working out in her Instagram post.

1. The joy workout

The resulting eight-and-a-half-minute Joy Workout lets you test these effects yourself. It leads you through six joy moves: reach, sway, bounce, shake, jump for joy and celebrate that looks like tossing confetti in the air.

2. Outdoor movement

Move outdoors, in a park or anywhere that gives you a dose of nature. Walking in a lively environment will boost your endorphins and you will feel happier and more enthusiastic. Even without any greenery around, spending time in sunlight and fresh air may help you feel better in your mind and body. Outdoor movements are beneficial for your overall health and well-being.

3. Group activities

When it comes to fitness, working out in group settings can boost motivation, burn more calories and make exercise fun. Move with other people, in a class or a training group, or casually, with friends or family.

4. Enjoy music

Move to the music, either through traditional exercises like jogging or cycling, or anything that gets your body moving like air guitar, drumming or singing karaoke.

5. Active games and sports

Make movement fun through play or competition, in any active game or sport. These activities create space for fun and healthy exercise. Playing a sport is a fun activity and keeps you fit mentally and physically. It engages the mind and body while energizing and de-stressing.

Follow more stories on Facebook & Twitter

Read more:
Top 5 ways to find joy in working out - Hindustan Times

Newly Established IMPOWR-YOU Center Engages Diverse Partners to Guide Research Aiming to Advance Treatments for Chronic Pain and Opioid Use Disorder -…

The Integrative Management of Chronic Pain and Opioid Use Disorder for Whole Recovery-Yale and Organizations United (IMPOWR-YOU) Research Center, launched at Yale School of Medicine nearly one year ago with a transformative $11.8 million grant through the NIH Helping End Addiction Long-term (HEAL) initiative, is seeking to advance integrated treatments for individuals who experience the overlap of chronic pain and opioid use disorder (OUD) or opioid misuse. Central to this mission is the engagement of people with lived experience of chronic pain and OUD/opioid misuse, alongside their caregivers, in the design, implementation, and dissemination of the Centers research. Amplifying the voices of people with lived experience increases the chances that their unique needs can be better addressed by clinicians and researchers, shares Declan Barry, PhD, IMPOWR-YOU Center Co-Principal Investigator.

With this in mind, a number of organizations representing people with lived experience of chronic pain, OUD or opioid misuse form part of the Centers organizational structure. It is one part of a broader Partner Engagement Core facilitated by Robert Kerns, PhD, Ryan McNeil, PhD, and Melissa Weimer, DO, MCR, and tasked with advising on research priorities, ethics, methods, analysis, and dissemination. The Partner Engagement Core has been developed with the support of such partners as the American Chronic Pain Association, Chronic Pain Research Alliance, Medication Assisted Recovery Services and the National Alliance for Medication Assisted Recovery, and the National Urban Survivors Union. In addition, a Veteran Engagement Panel brings to the Core the unique perspectives of patients treated for chronic pain and OUD/opioid misuse at the Veterans Health Administration. Says Dr. Kerns, there is rapidly growing awareness and supportive evidence that clinical research can benefit from engagement of people with lived experience [] Partners can play key roles in identification of significant scientific knowledge and practice gaps and development of key research questions to address these gaps.

Joining people with lived experience in the Partner Engagement Core are additional organizations representing Health Services and Health Systems, and Community and Professional Groups. The former aims to foster bi-directional exchange with health services and health systems partners to advise on implementation strategies and barriers as well as systems, policy, and practice implications of the Centers research findings. The latter brings to the table an interdisciplinary collective of regional and national entities engaged in activities relevant to chronic pain, opioid use disorder and opioid misuse, to advise on barriers to and facilitators of research dissemination and integration into education and practice.

As the new Center stretches its legs, conduct of anchoring research studies, PAIN CHAMP, led by William Becker, MD, and Anne Black, PhD, and SC-POWR, led by Dr. Barry, is well underway. Both studies were developed and refined in collaboration with the Partner Engagement Core, which will continue to advise as participant recruitment begins. In addition, an initial pilot project evaluating proactive opioid stewardship in patients hospitalized with chronic pain, OUD, and/or opioid misuse is underway under the direction of Dr. Weimer. On September 8th, the Center awarded its next round of pilot funding to Joao P. De Aquino, MD, whose project will evaluate pain sensitivity and synaptic nerve density among people initiating treatment for chronic pain and OUD.

Read the original here:
Newly Established IMPOWR-YOU Center Engages Diverse Partners to Guide Research Aiming to Advance Treatments for Chronic Pain and Opioid Use Disorder -...

Kidney resident macrophages have distinct subpopulations and occupy distinct microenvironments – University of Alabama at Birmingham

This novel finding will help guide successful therapeutic design and strategies for acute kidney injury and chronic kidney disease.

Macrophages are immune cells that engulf and digest pathogens, cancer cells or cellular debris. The kidneys like other tissues in the body contain kidney resident macrophages, or KRMs, from the time of birth. These KRMs protect the kidney against infection or injury and help maintain tissue health by phagocytosis of debris or dying kidney cells.

In other organs, the locations of macrophages affect their functions. Now James George, Ph.D., and colleagues at the University of Alabama at Birmingham report for the first time that the mouse kidney contains seven distinct KRM populations located in spatially discrete microenvironments, and that each subpopulation has a unique transcriptomic signature a measure of which genes are active, which suggests distinct functions.

Stratification of KRMs into specific zones within the kidney was previously unknown, George said. The spatial location of macrophages impacts their function in other tissues, such as the lung, spleen and liver, and shapes their response to an immunological challenge. Although many disease states have known connections with KRMs and targeting populations holds great therapeutic promise, successful design and implementation of such strategies are limited by our current understanding of KRM regulation and response to injury as a function of time.

The UAB study, published in the journal JCI Insight, is an application of spatial transcriptomics, which Nature Methods crowned as the 2020 Method of the Year.

George, co-corresponding author Anupam Agarwal, M.D., and UAB colleagues traced these KRMs in normal kidneys, and in kidneys after experimental injury caused by restricting the blood flow for 19 minutes. Such acute kidney injury can lead to chronic kidney disease, so knowledge of changes in the KRM subpopulations after injury is an important part of the KRM atlas of the mouse kidney. Such an atlas will serve as a point of reference for future studies into the role of the resident macrophage system in the normal and injured kidney.

The injured kidneys were examined at 12 hours and at one, six and 28 days after injury.

Following insult, we tracked the subpopulations as they appeared to relocate throughout the tissue, suggesting possible locomotion by these cells in response to injury, George said. Macrophages have the ability to move, similar to amoebas.

At 28 days after injury, three of the macrophage subpopulations largely returned to the locations where they were found before injury, but four subpopulations remained scattered throughout the kidneys. Thus, George said, our data support a long-hypothesized dysregulation of the immune system following acute kidney injury that could be a major factor contributing to increased risk for chronic kidney disease following an acute kidney injury event.

Humans have more than 1 million nephrons in each of their two kidneys. A nephron is the tiny, functional unit of the kidney, removing fluid from the blood, and then returning most of that fluid back to the blood while retaining waste urine that will flow through the ureter to the bladder. Different portions of the nephron perform different functions, and the researchers found that the distinct macrophage populations were associated with distinct portions of the nephron.

The research began with single-cell RNA sequencing of 58,304 KRMs isolated from whole mouse kidneys. Through analysis of 3,000 variable genes, they identified seven major distinct subpopulations that have unique transcriptomic signatures the messenger RNAs transcribed from active genes.

Anupam Agarwal, M.D.The differentially expressed genes in six of the clusters indicated at least one specific function. For example, George said, The most significant gene ontology terms in Clusters 1, 3 and 6 were involved in anti-bacterial, antiviral and anti-fungal responses. Cluster 2 contained terms related to responses to iron, phagocytosis and wound healing, suggesting involvement in homeostatic functions. Clusters 0 and 4 mapped to few terms, but the analysis contained references to tumor necrosis factor and apoptosis.

These disparate gene ontology mappings suggest that each cluster executes a distinct transcriptional program that could be a function of the location in which each cluster resides.

The locations for the clusters were found by placing a thin slice of the kidney on a Visium Spatial Gene Expression microscope slide that is about one-quarter of an inch square. The technology in the Visium system allowed the researchers to locate where in the kidney anatomy each subpopulation resides based on their transcriptomic signatures.

Two of the clusters in normal kidneys were located in the cortex, the outer region of the kidney. Four were in the medulla, the area below the cortex, and one was in the papilla, or central region of the kidney. One example of the importance of location was the coordinated positioning of three subclusters to protect the kidney from infection. The transcriptomes and locations of Clusters 1, 3 and 6 depict a strategic immune barrier from the ureter, the most common origin of kidney infections, George said.

Importantly, the KRM transcriptomic atlas at 28 days after injury with many KRM subpopulations no longer expressing their original profiles and existing within new locations was persistently altered. Given the continued disruption in transcriptional and spatial distribution beyond acute injury, KRMs may influence the transition to chronic kidney disease, George said. A single acute kidney injury event drastically increases the risk for the development of chronic kidney disease, although the mechanisms that underlie that transition remain unclear.

At UAB, George is a professor in the Department of Surgery, and Agarwal is a professor in the Department of Medicine Division of Nephrology. Co-first authors of the study, Resident macrophage subpopulations occupy distinct microenvironments in the kidney, are Matthew D. Cheung and Elise N. Erman, UAB Department of Surgery.

Other authors besides George, Agarwal, Cheung and Erman are Kyle H. Moore, Jeremie M. Lever, Jennifer R. LaFontaine and Rafay Karim, UAB Department of Surgery; Zhang Li and Bradley K. Yoder, UAB Department of Cellular, Developmental and Integrative Biology; and Gelare Ghajar-Rahimi, Shanrun Liu and Zhengqin Yang, UAB Department of Medicine.

Support came from National Institutes of Health grants DK079337, DK59600, DK118932, GM-008361 and AI007051; and American Heart Association grants 906401 and 827257.

At UAB, George holds the UAB Cardiovascular Surgical Research Chair, and Agarwal is interim dean of the Marnix E. Heersink School of Medicine. Surgery, Medicine, and Cellular, Developmental and Integrative Biology are departments in the Heersink School of Medicine.

View original post here:
Kidney resident macrophages have distinct subpopulations and occupy distinct microenvironments - University of Alabama at Birmingham

What Is Psoriasis And Can It Be Treated? – Forbes

Treatments for psoriasis fall into four categories: topicals, phototherapy, systemics and complementary or integrative medicine, according to the NPF. The choice of therapy depends on the severity of the disease, says Dr. Green.

Topical treatments are creams applied directly to the affected area, slowing the rapid production of skin cells and reducing inflammation. The most common topical medications are topical steroids, which contain an anti-inflammatory ingredient to heal swelling and redness and usually require a prescription from your doctor. However, topical steroids cant be used in some areas because they may cause side effects like bruising, pigmentation and redness.

In 2022, the U.S. Food and Drug Administration (FDA) approved a new, nonsteroidal topical cream for adults for the first time in 25 years called tapinarof. Patients can use this treatment from head to toe without any limitations, which is great for those who have mild to moderate psoriasis, says Dr. Green.

The FDA has also approved several over-the-counter topical treatments for psoriasis, such as lotions, shampoos, tars and bath foams that often contain coal tar and salicylic acid.

Phototherapy is a type of light therapy that a dermatologist may prescribe if topical treatments are ineffective. This therapy involves regularly exposing the skin to ultraviolet (UV) light, particularly UVB light. UVB rays are found in natural sunlight and slow the growth of skin cells.

There are several types of phototherapy, and its most effective when patients receive therapy at least two to five times a week for several weeks, according to the American Academy of Dermatology Association (AAD). Phototherapy is not prescribed for patients with skin cancer or in the case of any condition or medication that makes them more sensitive to UV light.

Systemic treatments are prescription drugs taken orally or through an injection or infusion and are usually prescribed when topicals and phototherapy are unsuccessful. These drugs, known as biologics or biosimilars, work throughout the body to target specific molecules inside immune cells and correct the overactive immune response causing psoriasis flares.

Biologics and biosimilars include medicines that come from live organisms, including animal cells and microorganisms like yeast and bacteria. Both treatments are highly regulated by the FDA and deemed by the organization to be safe and effective.

The best way to prevent psoriasis flares is to follow your dermatologists treatment recommendations, moisturize well and avoid trauma to the skin. Lowering stress can also help, says Dr. Stevenson.

The AAD suggests practicing stress-relieving activities, such as yoga, meditation and attending support groups. Lifestyle changes like reducing alcohol consumption, quitting smoking, avoiding skin exposure to dry, cold weather, treating infections and avoiding cutting yourself while shaving can also help prevent flares. Dietary considerations, such as increasing fruits and vegetables and avoiding foods that are high in fat, sugars, sodium and meat as well as limiting processed foods, may play an important role in minimizing psoriasis symptoms, according to an article in Immunity.

More here:
What Is Psoriasis And Can It Be Treated? - Forbes

Women and Drug Pay; Nondrug Pain Therapy; and Why Coffee Is Good – Medscape

Women Earn Less From Drug, Device Firms

Female physicians earn far less in compensation from drug and medical device companies than do their male peers, new research shows.

In fact, the gender-based pay disparity widened from 2013 to 2019, according to a study published in JAMA Surgery by faculty from the University of California and Weill Cornell Medicine surgery departments.

The study analyzed publicly reported financial compensation data in the Open Payments database from the 15 highest-grossing drug and medical device companies.

Big disparity: Female physicians received $41,320 on average compared with the $1,226,377 paid to male physicians, the study found.

Clear difference: Men received higher payments even after adjusting for academic rank, specialty, and the number of articles published, the study found.

New Rules on Nondrug Cancer Pain Therapy

New recommendations for the management of adult cancer pain give more attention to nondrug techniques such as massage, acupuncture, and music therapy.

The new guidelines were published in the Journal of Clinical Oncology and include discussion of integrative pain management techniques in a joint effort between the American Society of Clinical Oncology (ASCO) and the Society of Integrative Oncology (SIO).

The recommendations reflect a growing body of evidence suggesting that integrative therapies can be useful in cancer pain management.

Step forward: PreviousASCO guidelines only touched on evidence related to nonpharmacologic options for pain management.

Guidance needed: Clear clinical guidance on when and when not to use nondrug approaches is lacking, said Heather Greenlee, ND, PhD, co-chair of the SIO Clinical Practice Guideline Committee.

Coffee Cuts Cardio Illness

A new study found that two to three cups of coffee daily may reduce the risk for cardiovascular disease and death.

Caffeinated ground and instant coffee were linked with reduced risk for new-onset arrhythmia, includingatrial fibrillation, according to an analysis of the prospective UK Biobank published in theEuropean Journal of Preventive Cardiology.

Drinking up to five cups of coffee per day was associated with significant reductions in the risk for incidentcoronary heart disease, congestive cardiac failure, and ischemic stroke, with the lowest risk for people who consumed two to three cups per day.

Risk reduction: Death from any cause was significantly reduced for all coffee consumption, with the greatest risk reduction observed in people who drank two to three cups per day, whether caffeinated or not.

Why coffee? Caffeinehas antiarrhythmic properties throughadenosineA1 and A2A receptor inhibition. Coffee also has vasodilatory effects and contains antioxidant polyphenols, which reduce oxidative stress and modulate metabolism.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube

Originally posted here:
Women and Drug Pay; Nondrug Pain Therapy; and Why Coffee Is Good - Medscape

Best in the World 2022 winners presented by the Tulsa World – Tulsa World

The Best in the World was created by the Tulsa World to name the best of everything in Tulsa.

For years, the contest allowed Tulsans to nominate and then vote on more than 200 categories in 15 areas: automotive, beauty and wellness, community, drink, education, finance, food and dining, fun and leisure, health care, health-care professionals, home and garden, people of the year, pets, services and shopping.

This year we had more than 92,000 votes for this contest. Here is the complete list of winners for the 2022 Best in the World Contest, presented by the Tulsa World.

Automotive

Best Auto Dealership: Don Carlton Honda

Best Auto Detailer: Red Beard's Detail Shop

Best Auto Glass Repair: Safelite AutoGlass

People are also reading

Best Auto Paint: Gerber Collision & Glass

Best Auto Repair: Atlas Automotive

Best Auto Wrap: Outlaw Kustomz

Best Carwash: Tommy's Express Car Wash

Best Collision Repair/Body Shop: Gerber Collision & Glass

Best Limousine Service: VIP Limousine

Best Motorcycle Dealer: Myers-Duren Harley-Davidson

Best Oil Change: Jiffy Lube Oil Change

Best RV Dealer: Dave's Claremore RV

Best Tire Shop: Cecil & Sons Discount Tires

Best Wrecker Service: AAA

Beauty & Fitness

Best Barber Shop: All Good Barber Shop

Best Beauty Supply: Ulta Beauty

Best Cosmetic Surgery Center: Kimiko Medical Aesthetics

Best Day Spa: Emerge Medical & Well Spa

Best Gym/Fitness Center: Sports Performance Institute

Best Hair Salon: Ihloff Salon & Day Spa

Best Medical Spa: Soul Aesthetics

Best Nail Salon: Luxe Nail Bar

Best Place for a Massage: Emerge Medical & Well Spa

Best Place for Eyelash Extensions: Emerge Medical & Well Spa

Best Skin Care Facility: Soul Aesthetics

Best Tanning Salon: InnerGlow

Best Weight Loss Center: Emerge Integrative Medicine

Best Yoga Studio: Be Love Yoga Studio Tulsa

Community

Best Art Organization: AHHA

Best Customer Service: Hard Rock Hotel & Casino Tulsa

Best Hotel/Motel: Hard Rock Hotel & Casino Tulsa

Best Lake Resort: Shangri La Resort

Best Non-Profit Organization: George Kaiser Family Foundation

Best Place to Work: Hard Rock Hotel & Casino Tulsa

Drink

Best Bar/Lounge: Track 5. - Hard Rock Hotel & Casino

Best Local Brewery: Broken Arrow Brewing Company

Best Local Coffee Shop: Coffee House on Cherry Street

Best Margarita: 3 Tequilas

Education

Best Arts School: DanceWorkz Tulsa

Best College/University: Oral Roberts University

Best Daycare: The Synagogue | Congregation B'nai Emunah

Best Learning Center/Tutor: Kumon Math and Reading Center of TULSA - SOUTH

Best Martial Arts School: Jenks Martial Arts Academy

Best Preschool/Early Learning Center: Happy Hands Education Center

Best Private School (K-12): Monte Cassino Catholic School

Best Vocational School: Tulsa Technology Center

Finance

Best Accounting Firm: Tax Teks

Best Bank: First Oklahoma Bank

Best Credit Union: TTCU Federal Credit Union

Best Loan Company: Gateway First Bank

Best Tax Service: Desi Tax Service LLC

Best Wealth Management: Scissortail Wealth Management

Food & Dining

Bakery/Baked Goods: Merritt's Bakery

Best Asian Food: JINYA Ramen Bar - Tulsa

Best Authentic Mexican Food: Los Cabos Mexican Grill and Cantina

Best Bakery: Merritt's Bakery

Best Buffet: Texas de Brazil

Best Burger: Arnold's Old Fashioned Hamburgers

Best Casino Dining: Hard Rock Hotel And Casino Tulsa

Best Catering Company: Andolinis

Best Chocolatier: Glacier Chocolate & Coffee

Best Donut Shop: Daylight Donuts

Best Family Restaurant: The Bros. Houligan

Best Fine Dining: McGill's on 19

Best Food Truck: The Po'boy roller llc

Best Frozen Dessert: Braum's Ice Cream & Dairy Store

Best Happy Hour: Hodges Bend

Best Hot Dog/Coney: Coney I-Lander

Best Indian Food: India Palace

Best Italian Food: Mondo's Ristorante Italian

Best Outdoor Dining: East Village Bohemian Pizzeria

Best Pizza: Hideaway Pizza

Best Place for Breakfast: Neighborhood JAM

Best Place for Dinner: Nola's ...Creole & Cocktails

Best Place for Lunch: Queenies

Best Sandwich Shop/Deli: Trenchers Delicatessen

Best Seafood: White River Fish Market

Best Service/Waitstaff: McGill's on 19

Best Shaved Ice: Josh's Sno Shack

Best Sports Bar/Grill: Elgin Park

Best Steak: McGill's on 19

Best Tex-Mex Mexican Food: Ted's Caf Escondido

Fun & Leisure

Best Casino: Hard Rock Hotel & Casino Tulsa

Best Craft/Hobby Store: Hobby Lobby

Best Escape Room: Eleventh Hour Enigma

Best Family Entertainment: Tulsa Drillers Baseball

Best Large Live Entertainment Venue: BOK Center

Best Local Entertainment: Cain's Ballroom

See the original post here:
Best in the World 2022 winners presented by the Tulsa World - Tulsa World

Home – AAMSSA

AAMSSA is a non-profit society committed to the scientific and legitimate practice of Aesthetic and Anti-Aging Medicine to the benefit of the profession and the patient. AAMSSA is affiliated to the International Union of Aesthetic Medicine (UIME), South African Medical Association (SAMA), actively collaborates with the HPCSA when Scope of Practise for Aesthetic practitioners are considered as well as with the medical societies: The Association of Plastic, Reconstructive and Aesthetic Surgeons of Southern Africa (APRASSA), Dermatology Society Of South Africa (DSSA) and The South African Society for Dermatologic Surgery (SASDS).

We represent all medical doctors with a special interest in Aesthetic and Anti-Aging Medicine of South Africa and neighbouring countries. AAMSSA Membership supports career development, skills development, and the opportunity to belong to a community of like-minded individuals where the standards of treatment are world-class, ethical, and medically appropriate.

The mission of AAMSSA is to provide leadership and support to advance quality clinical, educational and professional standards of care for patients undergoing aesthetic procedures and treatment in the field of Aesthetic Medicine.

View original post here:
Home - AAMSSA

Anti-aging product – Wikipedia

Set of skin care products

Anti-aging creams are predominantly moisturiser-based cosmeceutical skin care products marketed with the promise of making the consumer look younger by reducing, masking or preventing signs of skin aging. These signs are laxity (sagging), rhytids (wrinkles), and photoaging, which includes erythema (redness), dyspigmentation (brown discolorations), solar elastosis (yellowing), keratoses (abnormal growths), and poor texture.[1] Anti-aging supplements are a set of ingestible products that are designed to reduce or diminish the effects of aging. This includes things such as vitamin supplements, powders and teas. They are designed to reduce or diminish the effects of aging. Many products seek to hide the effects of aging while others claim to alter the body's chemical balances to slow the physical effects of aging.[2] A comprehensive grading scale for anti-aging of the skin has been validated and categorizes skin aging as: laxity (sagging), rhytids (wrinkles), and the various categories of photoaging, including erythema (redness), dyspigmentation (brown discolorations), solar elastosis (yellowing), keratoses (abnormal growths), and poor texture.[3]

Despite great demand, many anti-aging products and treatments have not been proven to give lasting or major positive effects. One study found that the best performing creams reduced wrinkles by less than 10% over 12 weeks, which is not noticeable to the human eye.[4] Another study found that cheap moisturisers were as effective as high-priced anti-wrinkle creams.[5] A 2009 study at Manchester University, funded by the manufacturer of the cream, showed that a proprietary blend of ingredients had a positive effect after six months of daily application when extrapolated to a twelve month basis of comparison.[6][7] The statistical methods used to show this have been criticized.[8]

Traditionally, anti-aging creams have been marketed towards women, but products specifically targeting men are increasingly common.[9] Marketing of anti-aging products has been criticized as reinforcing ageism, particularly against women.[10] According to Toni Calasanti of Virginia Tech, anti-aging ads specifically reinforce the belief that older people should look like middle-aged people, and that old age comes with a loss of gender identity.[11]

Anti-aging creams may include conventional moisturising ingredients. They also usually contain specific ingredients claimed to have anti-aging properties, such as:

See the original post:
Anti-aging product - Wikipedia

Skin anti-aging strategies – PMC – PubMed Central (PMC)

Dermatoendocrinol. 2012 Jul 1; 4(3): 308319.

1Centre of Dermatovenereology; Vilnius University Hospital Santariskiu Klinikos; Vilnius, Lithuania

2Departments of Dermatology, Venereology, Allergology and Immunology; Dessau Medical Center; Dessau, Germany

2Departments of Dermatology, Venereology, Allergology and Immunology; Dessau Medical Center; Dessau, Germany

2Departments of Dermatology, Venereology, Allergology and Immunology; Dessau Medical Center; Dessau, Germany

2Departments of Dermatology, Venereology, Allergology and Immunology; Dessau Medical Center; Dessau, Germany

1Centre of Dermatovenereology; Vilnius University Hospital Santariskiu Klinikos; Vilnius, Lithuania

2Departments of Dermatology, Venereology, Allergology and Immunology; Dessau Medical Center; Dessau, Germany

These authors contributed equally to this work.

This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

Skin aging is a complex biological process influenced by a combination of endogenous or intrinsic and exogenous or extrinsic factors. Because of the fact that skin health and beauty is considered one of the principal factors representing overall well-being and the perception of health in humans, several anti-aging strategies have been developed during the last years. It is the intention of this article to review the most important anti-aging strategies that dermatologists have nowadays in hand, including including preventive measurements, cosmetological strategies, topical and systemic therapeutic agents and invasive procedures.

Keywords: aging, anti-aging, antioxidants, laser, peeling, fillers, botulinum toxin, hormone replacement therapy, cell regulators, prevention

Skin aging is a part of a natural human aging mosaic which becomes evident and follows different trajectories in different organs, tissues and cells with time. While the aging signs of internal organs are masked from the ambient eyes, the skin provides first obvious marks of the passing time.

Skin aging is a complex biological process influenced by combination of endogenous or intrinsic (genetics, cellular metabolism, hormone and metabolic processes) and exogenous or extrinsic (chronic light exposure, pollution, ionizing radiation, chemicals, toxins) factors.1 These factors lead together to cumulative structural and physiological alterations and progressive changes in each skin layer as well as changes in skin appearance, especially, on the sun-exposed skin areas.2-12 In contrast to thin and atrophic, finely wrinkled and dry intrinsically aged skin, premature photoaged skin typically shows a thickened epidermis, mottled discoloration, deep wrinkles, laxity, dullness and roughness.13-18 Gradual loss of skin elasticity leads to the phenomenon of sagging.19 Slowing of the epidermal turnover rate and cell cycle lengthening coincides with a slower wound healing and less effective desquamation in older adults. This fact is important when esthetic procedures are scheduled.20 On the other side, many of these features are targets to product application or procedures to accelerate the cell cycle, in the belief that a faster turnover rate will yield improvement in skin appearance and will speed wound healing.21 A marked loss of fibrillin-positive structures22 as well as a reduced content of collagen type VII (Col-7), may contribute to wrinkles by weakening the bond between dermis and epidermis of extrinsically age skin.23 Sun-exposed aged skin is characterized by the solar elastosis. The sparse distribution and decrease in collagen content in photoaged skin can be due to increased collagen degradation by various matrix metalloproteinases, serine, and other proteases irrespective of the same collagen production.24-28 In older skin, collagen looks irregular and disorganized, the ratio of Col-3, to Col-1 has been shown to increase, due, significantly, to a loss of Col-1.29 The overall collagen content per unit area of the skin surface is known to decline approximately 1%/year.30 Glycosaminoglycans (GAGs) are among the primary dermal skin matrix constituents assisting in binding water. In photo-aged skin, GAGs may be associated with abnormal elastotic material and thus be unable to function effectively.31 The total hyaluronic acid (HA) level in the dermis of skin that age intrinsically remains stable; however, epidermal HA diminishes markedly.32

Three primary structural components of the dermis, collagen, elastin and GAGs have been the subjects of the majority of anti-aging research and efforts for aesthetic-anti-aging strategies pertaining to the skin, from anti-wrinkle creams to various filling agents.21

Presentation of aging of the entire face is associated with the gravity impact, muscles action, loss of volume, diminishing and redistribution of superficial and deep fat, loss of bony skeleton support what all together lead to the face sagging, changes in shape and contour. Regardless of the fact that aging is a biological inevitable process and not a pathological condition it is correlated with various skin and body pathologies, including degenerative disorders, benign and malignant neoplasms.

The successful aging paradigm, focuses on health and active participation in life, counters traditional conceptualizations of aging as a time of disease and is increasingly equated with minimizing age signs on the skin, face and body.33-35 From this perspective, preventative aesthetic dermatology might supplement the request for healthy aging, treat or prevent certain cutaneous disorders, notably skin cancer, and delay skin aging combining local and systemic methods of therapy, instrumental devices and invasive procedures.36,37 The mainspring of any skin anti-aging therapy is to achieve a healthy, smooth, blemish-free, translucent and resilient skin.38 In clinical practice, to look better doesnt mean to look younger. That is why it is so important to understand patients wishes and to orientate them to the treatment modality that will give the most satisfying results whereas knowing all available treatment techniques.39 The age, previous procedures or surgery, general health status, type of the skin, style of life and many other factors should be taken into consideration before choosing the strategy for the individual case. The desired therapeutic anti-aging effect of the skin is continuous, step-by step process, which combines various methods of the skin bio-revitalization and rejuvenation, augmentation, restoration of each skin layer individually and in the light of many other factorsfrom a style of the life to the immune, genetic, emotional and health status in general. This review will emphasize the most important topical and systemic therapeutic agents and trends in the use of invasive procedures.

The skin anti-aging strategies attempted to reverse the dermal and epidermal signs of photo- and chronological aging can be grouped under the following approaches ().

Table1. Skin antiaging approaches

Healthy and functioning skin barrier is important protector against dehydration, penetration of various microorganisms, allergens, irritants, reactive oxygen species and radiation. The skin barrier may be specifically adjusted to allow penetration. For this reason daily skin care may increase skin regeneration, elasticity, smoothness, and thus temporarily change the skin condition.40,41 However, it is necessary to stop the degradation of the skin primary structural constituents, such as collagen, elastin, to prevent the formation of wrinkles. Although the technology required to suitably deliver these compounds into the skin has not yet been developed, some products do promote the natural synthesis of these substances except elastin enhancing.42-45 Another integral approach preventing wrinkle formation is the reduction of inflammation by topical or systemic antioxidants which should be used in combination with sunscreens and retinoids to enhance their protective effects.21

Chronic photodamage of the skin manifests itself as extrinsic skin aging (photoageing). DNA photodamage and UV-generated reactive oxygen species (ROS) are the initial molecular events that lead to most of the typical histological and clinical manifestations of chronic photodamage of the skin. Wrinkling and pigmentary changes are directly associated with premature photo-aging and are considered its most important cutaneous manifestations. The strategies aimed at preventing photo-aging include sun avoidance, sun protection using sunscreens to block or reduce skin exposure to UV radiation, retinoids in order to inhibit collagenase synthesis and to promote collagen production, and anti-oxidants, particularly in combination, to reduce and neutralize free radicals (FR).21,46

Interventional studies indicate that it is in fact possible to delay skin aging and to improve skin conditions through administration of selected nutritional supplements. Nutritional antioxidants act through different mechanisms and in different compartments, but are mainly FR scavengers: (1) they directly neutralize FRs, (2) they reduce the peroxide concentrations and repair oxidized membranes, (3) they quench iron to decrease ROS production, (4) via lipid metabolism, short-chain free fatty acids and cholesteryl esters neutralize ROS.47 Endogenous antioxidant defenses are both non-enzymatic (e.g., uric acid, glutathione, bilirubin, thiols, albumin, and nutritional factors, including vitamins and phenols) and enzymatic [e.g., superoxide dismutases, glutathione peroxidases (GSHPx), and catalase]. The most important source of antioxidants is provided by nutrition. To the most known systemic antioxidants belong vitamin C, vitamin E, carotenoids, and from the trace elements copper and selenium.48-50 There are also studies demonstrating that vitamins C and E combined with ferulic acid impart both a sunscreen and an anti-oxidant effect.51

There are two main groups of agents that can be used as anti-aging cream components, the antioxidants and the cell regulators. The antioxidants, such as vitamins, polyphenols and flavonoids, reduce collagen degradation by reducing the concentration of FR in the tissues. The cell regulators, such as retinols, peptides and growth factors (GF), have direct effects on collagen metabolism and influence collagen production.

Vitamins C, B3, and E are the most important antioxidants because of their ability to penetrate the skin through their small molecular weight.52 The water-soluble, heat-labile local L-ascorbic acid (vitamin C) in concentrations between 5 and 15% was proven to have a skin anti-aging effect by inducing the production of Col-1, and Col-3, as well as enzymes important for the production of collagen, and inhibitors of matrixmetalloproteinase (MMP) 1 (collagenase 1).43,53 Clinical studies have proven that the antioxidative protection is higher with the combination of vitamins C and E than with the vitamin C or E alone.54,55 Niacinamide (vitamin B3) regulates cell metabolism and regeneration, and it is used in 5% concentration as an anti-aging agent.56 In some studies, improvement of skin elasticity, erythema and pigmentations after 3 mo of topical treatment has been observed.52,54 Vitamin E (-tocopherol) used as a component of skin products has anti-inflammatory and antiproliferative effects in concentrations between 2 and 20%. It acts by smoothing the skin and increasing the ability of the stratum corneum to maintain its humidity, to accelerate the epithelialization, and contribute to photoprotection of the skin. The effects are not as strong as with vitamins C and B3.57

An in vivo study has proven that the topical application of green tea polyphenols before UV exposure leads to an increase of the minimal erythema dose, decreases the number of Langerhans cells and reduces DNA damage in the skin.58 Other botanicals that act as antioxidants are for example the isoflavones from soya.

Cell regulators, such as vitamin A derivatives, polypetides and botanicals, act directly on the collagen metabolism and stimulate the production of collagen and elastic fibers.

Vitamin A (retinol) and its derivates (retinaldehyde and tretinoin) are also a group of agents with antioxidant effects. They can induce the biosynthesis of collagen and reduce the expression of MMP 1 (collagenase 1). Retinol is, at the moment, the substance that is most often used as an anti-aging compound and, compared with tretinoin, causes less skin irritation.59,60 It has been shown that retinol has positive effects not only on extrinsic but also on intrinsic skin aging and has a strong positive effect on collagen metabolism.60,61 Tretinoin, a nonaromatic retinoid of the first generation, is approved for application as an anti-aging treatment in a concentration of 0.05% in the United States. It has been shown to be able to reduce the signs of UV-induced early skin aging, such as wrinkles, loss of skin elasticity and pigmentation.

Polypeptides or oligopeptides are composed of amino acids and can imitate a peptide sequence of molecules such as collagen or elastin. Through topical application, polypeptides have the ability to stimulate collagen synthesis and activate dermal metabolism.62

There are various in-office procedures, most of which are intended to resurface the epidermis: to remove the damaged epidermis and replace the tissue with remodeled skin layers and sometimes spur the formation of new collagen.21,63 It is possible that the potential of GF, cytokines and telomerase will eventually be harnessed via technological advancement and innovation in the burgeoning fields of tissue engineering and gene therapy in the nearest future.64

Chemical peels are methods to cause a chemical ablation of defined skin layers to induce an even and tight skin as a result of the regeneration and repair mechanisms after the inflammation of the epidermis and dermis. Chemical peels are classified into three categories.65,66 Superficial peels [--, lipo-hydroxy acids (HA), trichloroacetic acid (TCA) 1030%] exfoliate epidermal layers without going beyond the basal layer; medium-depth peels (TCA above 30 to 50%) reach the upper reticular dermis; deep peels (TCA > 50%, phenol) penetrate the lower reticular dermis. The depth of peeling depends not on the substance used only, but on its concentration, pH of the solution and time of application.66 A number of skin modifications have been reported after several weeks: epidermal architecture returns to normal, melanocytes are present and distributed uniformly, basal cells contain small melanin grains distributed homogeneously, the thickness of the basal membrane is homogeneous, in the dermis, a new sub epidermal band of collagen appears, elastic fibers form a new network, often parallel to those of collagen.67 If superficial peelings target the corneosomes, cause desquamation, increase epidermal activity of enzymes, lead to epidermolysis and exfoliation,68,69 medium-depth peels cause coagulation of membrane proteins, destroy living cells of the epidermis and, depending on the concentration, the dermis. Deep peels coagulate proteins and produce complete epidermolysis, restructure of the basal layer and restoration of the dermal architecture.69 The depth of peel correlates with the potential side-effects, like hyperpigmentation, solar lentigines, risk of post-operative infections, especially herpetic ones.66,70 The mechanism by which the chemical peel takes effect is not clearly elucidated. An increase in collagen fiber content, water and GAG in the dermis has been reported.71,72 There is a suggestion that improvements in skin elasticity and wrinkles after chemical peeling can be attributed to increase of Col-1 with or without Col-3, elastic fibers, as well of a dense rearrangement of collagen fibers.73-76

Nonablative skin rejuvenation or subsurfacing comes as a low risk and short downtime technology which can improve aging structural changes without disruption of cutaneous integrity.77 The mechanism of action is supposed to be a selective, heat induced denaturalization of dermal collagen that leads to subsequent reactive synthesis. Nonablative skin rejuvenation is not a precise term since rejuvenation is a controlled form of skin wounding aimed at achieving a more youthful appearance after the wound heals.39

Treatment of photoaged skin has been divided into treatment of ectatic vessels and erythema, irregular pigmentation, and pilosebaceous changes (Type I) and into the improvement of the dermal and subcutaneous senescence (Type II).77 The epidermis and superficial dermis can be selectively damaged by two basic mechanisms: (a) by targeting discrete chromophores in the dermis or at the dermal-epidermal junction or (b) by utilizing mid infrared (IR) lasers.78

The devices for treatment of vascular and/or pigment irregularities include lasers emitting light at 532-, 585-, 595-, 755-, 800-, and 1064-nm wavelengths as well as filtered light generated by IPL systems equipped with different cut-off filters39,79(). Lasers emitting 1,320,80 1,450,81 and 1,540 nm82 using interstitial and intracellular water as target chromophores and pulsed dye lasers (PDL)83 using oxyhemoglobin as the primary chromophore are now employed for Type II photo rejuvenation only. The clinical efficacy of these nonablative modalities are weaker than that of the ablative methods, however, new collagen formation and clinically observable improvement in wrinkles can be observed.84,85 Reduction of facial wrinkles by using IPL devices has shown less effect comparing to laser technology,86 but for type I photo rejuvenation, IPL systems have in general shown considerably better results than laser systems operating at subpurpuric energy levels.87-90 Ultrastructural and histological analysis confirmed effectiveness of absorption of light (532, 585, 595, with or without 1064-nm Nd:YAG laser) in the blood vessels of the superficial dermis, resulting in the release of inflammatory mediators and GF into the interstitium followed by stimulated fibroblast activity and initiation of tissue repair and enhanced collagen and elastin neoformation replacing the originally damaged elastic tissue.84,91,92 An increase in grenz zone thickness,91 monoclonal chondroitin sulfate and III procollagen staining as well as quantification of Col-193 was measured after couple of treatments with PDL. The increase in dermal collagen has also been confirmed by noninvasive ultrasonographic analysis94 and radioimmunoassay.95 Nonablative skin rejuvenation should not yet be considered an alternative for laser resurfacing.39 However there are interesting data showing comparative histological changes between the ablative and nonablative modalities.96

Figure1. 45-y-old female with signs of photoaged skin: dyschromia of the skin, multiple lentigines. (A) before, (B) after one treatment with IPL with 550 nm cut-off filter.

Histological sections of skin before and after treatment with the different IPL devices have shown the formation of new collagen in the papillary and reticular dermis, as well as an increase in the number of fibroblasts and proportional decrease in the amount of solar elastosis is also usually found.92,97-99 If vascular and/or pigment disturbances improvement are immediate, the collagen remodeling response is delayed and maximum results are seen only between 3 and 12 mo after treatment.39

Laser resurfacing has been shown to be effective in counteracting photoaging through entire epidermal ablation, collagen shrinkage, stimulation of neocollagenesis, extensive dermal remodeling, regeneration of cellular organelles and intercellular attachments100 but parallelly, results in long recovery time are associated with risks of severe long lasting side effects, such as persistent erythema, hypo- or hyperpigmentation, infection or scarring.101-104

Recently, fractionated CO2-, erbium glass or erbium-YAG lasers have been introduced to reduce downtime and side effects.105 These devices emit light in a pixilated fashion onto the skin, producing an array of microthermal zones in the dermis.105-108 The controlled thermal stress to the epidermis and the dermal compartment is followed by a wound healing response ultimately leading to re-epithelization and dermal remodeling.109

Although the underlying molecular changes induced by different ablative and non-ablative as well as thermal and non-thermal skin rejuvenation treatments are not fully understood, there are investigations suggesting important roles of heat shock proteins (HSP), transforming growth factor (TGF-), different MMPs, synthethases, hyals and hyaluronic acid (HA).109-113 Type I and type III procollagen mRNA was also elevated for at least 6 mo.114

Monopolar RF is a noninvasive way to obtain skin tightening39 and immediate collagen contraction with a single treatment. Unlike lasers, the RF technology produces electric current, which generates heat through resistance in the dermis and as deep as the subcutaneous fat.78 Unfortunately there is a lack of long-term studies of efficacy and analysis of side effects for the skin using this method of skin rejuvenation.

It is obvious that different treatment modalities using visible light devices have resulted in varying clinical effects and allow to select individual treatment parameters for different indications.115 For this reason, careful simultaneous evaluation of any pigment disturbances, vascular abnormalities, wrinkles, and cutaneous sagging as skin layers are all linked is highly recommended.

The goal of skin biorejuvenation is to increase the biosynthetic capacity of fibroblasts, inducing the reconstruction of an optimal physiologic environment, the enhancement of cell activity, hydration, and the synthesis of collagen, elastin and HA (hyalorunic acid). The desired effect could be achieved by the microinjections in the superficial dermis of products containing only one active ingredient or cocktails of different compounds which are perfectly biocompatible and totally absorbable: HA, vitamins, minerals, nutrients, hormones, GF, amino acids, autologous cultured fibroblasts, homeopathic products, etc.116-121 The distinct formulations can induce strikingly divergent molecular and cellular processes in fibroblasts in vitro.122 However, more detailed studies are required to elucidate whether and how the cellular and molecular processes are involved in facial skin rejuvenation in vivo, whether these processes are similarly efficient, independent of the age of the patients. The proof of concept, including long-term efficiency, optimal injecting protocols are still lacking too.123,124

Products injected within or beneath the skin to improve its physical features by soft tissue augmentation are known as fillers.125-129 There are autologous (fat, cultured human fibroblasts), collagen (bovine-derived, human-derived from tissue culture), HA (nonanimal stabilized or viscoelastic HA from bacterial fermentation), synthetic or pseudo-synthetic implants (silicone, polymethacrylate microspheres, poly-L-lactic acid, calcium hydroxylapatite microspheres suspended in aqueous polysaccharide gel, alkyl-imide gel polymer). These may be grouped into temporary, semipermanent (lasting between 12 y), or permanent materials (lasting longer than 2 y).

GAG and particularly HA or hyaluronan are major components of the cutaneous extracellular matrix involved in tissue repair of all animal tissues.130-132 HA exhibits no species or tissue specificity. As a physical background material, it has functions in space filling, lubrication, shock absorption, and protein exclusion. In addition, HA has been implicated as a regulator of cell proliferation and locomotion.133-135 Injection of HA is thought to promote skin rejuvenation by increasing both hydration and fibroblast activation.136-140 HA injected into the skin can stimulate fibroblasts to express Col-1, MMP-1 and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1)122,141 as well as is participating in wound healing, modulation of inflammatory cells, interaction with proteoglycans of the extracellular matrix, and scavenging of FR.142 All these features of HA have made it to be useful as an ideal structural compound and have raised injections of HA products to the most acceptable and scientifically investigated gold standard procedures for skin rejuvenation and augmentation ().

Figure2. Patient showing the difference of the nasolabial fold: non-treated left side (with site marks for planned HA injection) and right side straight after injection of only 0.5 ml of nonanimal stabilized cross-linked HA (Stalagmite technique on the right cheek).

Natural HA has a half-life in tissue of only 1 to 2 d before undergoing aqueous dilution and enzyme degradation in the liver to carbon dioxide and water.143 Produced from bacterial (Staphylococcus equine) fermentation and modified by chemical cross-linking to improve their resistance to enzymatic degradation and prolong their effect, non-animal reticulated HA fillers are more pure, more viscous, usually well tolerated and rarely elicit adverse and immunological reactions.130,144-146 The duration of effect for HA fillers ranges from 3 to 12 mo. The long-lasting dermal fillers maintain the position 12 y or even more.147 Modern HA fillers differ in the particulate size, cross-linking and the type of cross-linking agent used in the HA; phasic structuremono/biphasic, concentration of HA and presence of an anesthetic agent in each syringe.148-151 Besides composition, currently available products differ based on approved indications, duration of aesthetic effect, putative mode of operation, recommended depth of product placement, injection technique, suitability for different facial areas, and common adverse events.152

One of long-lasting synthetic semi-permanent dermal fillers is calcium hydroxyl apatite based filler (CaHA) suspended in an aqueous carboxymethylcelluose gel carrier.150-155 The CaHA particles act as a scaffold for new tissue formation and stimulate collagen formation around the microspheres leading to a thickening of the dermis over time.147 The spherical CaHA particles are gradually phagocytosed, degraded as calcium and phosphate and eliminated via the renal system. CaHA is biocompatible with an identical composition to bones with a low potential for antigenicity, foreign body reaction, and minimal inflammatory response. No osteoblast activity has been observed in soft tissue.155

The application of poly-L-lactic acid (PLA) in soft tissue augmentation exploits a mechanism of action not seen in any other soft tissue filler like a treatment plan, preparation of injection material, and injection technique is distinct as well.156 After the initial response lasting one week or less a delayed but progressive volumizing effect begins.157 The process of hydration, loss of cohesion and molecular weight, and solubilization and phagocytosis of PLA by the hosts macrophages, degrades PLA into lactic acid microspheres and eliminates CO2 by way of respiratory excretion. Crystals are left behind to stimulate collagen and a granulomatous reaction. This inflammatory reaction elicits resorbtion and the formation of fibrous connective tissue about the foreign body, causing dermal fibroplasia that leads to the desired cosmetic effect.158

Although subjective patient satisfaction is high in many of the studies with skin fillers and skin thickness as measured using wrinkle scale ratings of appearance, long-term efficacy and clinical safety data are lacking because patients are likely to continue to undergo subsequent cosmetic interventions.159

Autologous Platelet-rich Plasma (PRP) has attracted attention for skin rejuvenation. PRP is derived from fresh whole blood, which contains a high concentration of platelets.160 Various GF, including platelet-derived growth factor (PDGF), transforming growth factor (TGF), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF), are secreted from the -granules of concentrated platelets activated by aggregation inducers.161 These factors are known to regulate processes including cell migration, attachment, proliferation and differentiation, and promote extracellular matrix (ECM) accumulation by binding to specific cell surface receptors.162,163 It has been shown that PRP may induce the synthesis of collagen and other matrix components by stimulating the activation of fibroblasts, thus, rejuvenating the skin.164-167 However, the molecular mechanisms underlying PRP-inducing wound healing processes are still largely unknown and experimental studies confirming the effects of PRP on aged fibroblasts are very limited.

Botulinum toxin (BTX) has no effect on skin texture and cannot discontinue the skin aging process. However, regular BTX injections can slow down the visible aging process by helping in the management of certain dynamic facial lines and wrinkles168-170(). Current treatment options of exaggerated frown lines, glabellar lines or crow feet such as surgery or implants, do not address the underlying cause of these lines, namely the excessive nerve stimulation. The mechanism of action of BTX makes it an ideal agent to target the major cause of these dynamic lines.171

Figure3. Patient showing glabellar and crows feet wrinkles. (A) pre-injection, (B) after injection with botulinum toxin.

Seven constitutionally similar but antigenically distinct subtypes of neurotoxin (A-G) are produced by different strains of the anaerobic, gram-positive bacterium Clostridium botulinum.172-177 BTX- subtype A (BTX-A) is the most potent. BTX-A produces temporary chemical denervation by blocking the presynaptic release of acetylcholine (Ach) at the neuromuscular junction (NMJ).178 The specific heavy chain is associated with the internalization of the toxin and binds it irreversibly to the motor nerve end-plates with a high affinity to specific receptors (sialoglycoproteins) in the plasma membrane of cholinergic nerve endings. This induces receptor-mediated endocytosis of the toxin. The light chain that is responsible for the toxicity splits off in the cell, and inactivates a synapse-specific protein synaptosomal-associated protein of 25 kDa (SNAP-25) which is one of several proteins required for Ach exocytosis and release into the NMJ.179

The toxin binds to presynaptic neurons of selected muscles rapidly (under an hour) and specifically. Clinically reversible chemical denervation and selective muscle relaxation or paralysis starts after 24 to 48 h and may not be completed for up to 2 weeks.173-177 In muscle, approximately on day 28, nerve sprouts mediate a partial restoration and new neuromuscular junctions are formed in the vicinity of the old junctions. Another factor explaining the regaining of muscle function could be an increase in the area of muscle membrane sensitive to acetylcholine.180 On days 6291, complete muscle function recovery can be demonstrated.179,181

Muscular changes in the form of atrophy were demonstrated in animal studies, and were completely reversible after 46 mo. In human muscle, no lasting atrophy could be detected even after repeated injections, only a predominance of type I fibers.179 The usual duration of effect is 36 mo with individual variations.173-177

Dosing of BTX-A is essential in achieving precise and predictable effects. The biological activity given in mouse units (MU) and the weight of the molecule is not associated with the dosage. One MU is equivalent to the amount of toxin at which, after intraperitoneal administration, half of the poisoned Swiss-Webster mice die (50% lethal dose; LD50).182 The amounts of BTX-A used for the treatment are 25100 times less than the LD50, so that the FDA classifies BTX-A as therapeutically safe.183 BTX-A does not cross the blood-brain barrier or pass through the skin.179

Several commercial preparations of BTX-A products which are produced from different strains of bacteria by different purification methods and therefore have distinct components and properties, requirements of storage, shelf-life, and dose are currently available for aesthetic uses.184,185

A thorough understanding and evaluation of the relevant anatomy and physiology of the muscles and possible alterations in the area to be injected is essential. Dosage for the patients depends on the area, muscle mass, gender and other factors individually. Contraindications include conditions of peripheral motor neuropathic diseases or neuromuscular functional disorders, coadministration with aminoglycoside antibiotics or other agents that interfere with neuromuscular transmission and may potentiate general weakness, treatment of patients with inflammatory skin disorders at the injection site, history of reaction to toxin, pregnancy and lactation, age younger than 12 y, participation in occupations that necessitate a wide range of facial expressions.171,186-188

Given the short-term and localized effects of BTX-A injections, it is reassuring that any potential adverse reactions known to date may also be short lived, localized, and reversible in a dose-dependent period of 68 weeks. Systemic or serious side effects in general are rare, immune-mediated disorders or other idiosyncratic reactions are unknown.189,190 The development of antibodies to BTX-A may be related to exposure to high doses of toxin and seems to be related to decreased BTX-A efficacy.191,192 Current batches of BTX-A (manufactured after 1997) have lower albumin concentration and higher toxin-specific activity, which may contribute to reduced clinical antigenicity.182,193,194

The incidence of complications in many cases depends on the proper application and the qualification of the physician. However, it has always to be considered that the benefits of this treatment are transient and repeated injections are necessary for a long-term effect.195

It is well known that there is a progressive decrease of hormone synthesis with age. Levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1), melatonin (nocturnal), TSH, thyroid hormones (T3), dehydroepiandrosterone (DHEA) (sulphated form and its urinary 17-keto-metabolites), estrogens and testosterone are progressively decreasing. The main hormonal deficits in humans are menopause, andropause and partial androgen deficiency of the aging male.196-199 DHEA substitution has been proven to lead to an improvement of body condition, sexual activity, bone density, and well-being.200

In a randomized and placebo-controlled study of 280 older men and women (6079 y of age), each subject received 50 mg of DHEA daily for a year. The women showed an improvement of the libido, skin health, and osseous density.201-203Furthermore, another study conducted by Rudman et al. has pointed out that the application of GH decreased the signs of biological aging. The treatment led to an improved body condition, with an increase of muscle mass and osseous density and a decrease of adipose tissue. Moreover, an increase of skin thickness was observed.199

Melatonin has been shown to have a favorable influence on the aging process, because it has an inverse effect with regard to body weight; food restriction raises the levels of melatonin and decreases its age-related decrease. With increasing age comes a decrease of melatonin production, which may have a connection to sleep disorders suffered by elderly people. It also has be shown that melatonin can prevent tumor development and growth. Interestingly, a study showed that patients with tumors had decreased levels of melatonin compared with healthy individuals.204-207

HRT with testosterone is absolutely indicated in older men who are either symptomatic or have a low serum testosterone level. Either a decrease of testosterone or a loss of the circadian rhythm of testosterone secretion has been observed in a high percentage of older men. Clinical symptoms include general weakness, sexual dysfunction, diminished muscle and bone mass, and decreased erythropoiesis. A low testosterone level has been shown in epidemiological studies to lead to a higher morbidity and mortality rate and to a higher prevalence of depression, coronary heart disease, and osteoporosis. Insulin resistance has been shown to play an important role in the development of hypogonadism in older men. Thus, obese men and men with type 2 diabetes, show significantly lower testosterone levels compared with subjects in control groups.199

HRT with estrogen and progesterone has been long considered to have anti-aging effects; results of larger studies though, particularly of the Womens Health Initiative, have shown that an anti-aging effect is not necessarily to be expected. On the contrary, HRT has been accused to have a higher cardiovascular risk and increase of the risk of breast cancer. However, it has clear, positive preventive effects on osteoporosis, and an early, low-dose estrogen monotherapy can be considered to have advantages.208

While natural aging is genetically determined, extrinsic aging can be prevented. Aesthetic dermatology should contribute to healthy aging not only in cosmetic means by trying to erase time vestiges in skin but by also playing a significant part in prevention, regeneration, and delaying of skin aging combining knowledge of possible local and systemic therapy, instrumental devices and invasive procedures, filling the lack of scientific investigations and becoming one of the important focuses of the aging research.

No potential conflicts of interest were disclosed.

186. Botox (Package Insert). Allergan, Inc.

More here:
Skin anti-aging strategies - PMC - PubMed Central (PMC)

22 Ways To Look and Feel 5 Years Younger – Men’s Health

From Silicon Valley investors to the new wave of longevity tech start-ups, a growing body sees ageing as something to be tracked and hacked, with your stats as much within your control as your gym PBs. But how easy is it for the average man to better his biological age? MH reviews the latest science.

Want to put the breaks on brain-ageing? A University of California, Riverside study found those who practised three skills simultaneously say, learning a language, mastering gymnastics and taking a career-boosting online tutorial had cognitive abilities decades below their actual age. In a good way, we mean. Download the Udemy app, with over 100,000 video courses, and upgrade your commute.

If you neglected to pack trainers today, dont sweat: in a University of North Florida study, participants who ran barefoot for 15 minutes improved their powers of recall by 16% in subsequent tests, while shoe-clad sprinters saw no improvement. Researchers credit the additional proprioceptive demands. Joggings backwards has been shown to have a similar effect.

Patchareeporn SakoolchaiGetty Images

Want to wind back your biological clock without lifting a finger? Tag a sauna session on to your next workout. The University of Eastern Finland tracked more than 2,300 middle-aged men and found that those who used a sauna two or more times a week lived longer, while further studies have linked it to slower brain ageing, too.

Shrinking your calorie intake can do more than trim excess timber. Its one of the most promising methods of slowing ageing, says Varun Dwaraka, bioinformatician at anti-ageing tech company TruDiagnostic, who points to its benefits to blood sugar regulation and vascular density in the brain. That doesnt mean all-day deprivation, though. Experiment with one of these protocols.

Eat your meals during daylight hours particularly during the winter months. Its been linked to a slower rate of ageing in studies conducted on animals.

Schedule a five-day cut. A fasting-mimicking diet in which you drop your calories for a period of just a few days has been shown to switch on anti-ageing genes in research by longevity biochemist Valter Longo.

Or quit meatfor a few days a week. Some researchers believe our bodies infer a state of scarcity when on a plant-only diet, meaning flexitarianism might deliver some of the benefits of fasting.

MoMo ProductionsGetty Images

Cardio alone wont cut it. Maintaining strength is arguably the most important thing you can do to ensure high quality of life in middle-age and beyond, says Professor Matt Kaeberlein, an expert in ageing at UW Medicine. In fact, one study in The Journals Of Gerontology found that older men with greater muscle strength were 50% less likely to die prematurely. Focus on compound movements and lift three or four times each week, jsays Professor Kaeberlein.

Plant polyphenols such as fisetin and quercetin have the power to seek and destroy senescent cells, aka zombie cells. These are cells that essentially have been paused and start to secrete inflammatory markers, leading to frailty and disease, says TruDiagnostics Ryan Smith. Berries, apples, kiwis and grapes are top sources. As a bonus? Raising vitamin C levels has also been linked to maintaining muscle mass over the age of 50.

This year, scientists in Cambridge pioneered a new technique to reverse ageing in human skin cells by 30 years. But until thats available, try these low-cost hacks:

Drink from the (chocolate) fountain of youth. A study by Koreas Seoul National University found that 12g of cacao a day can reverse sun-related ageing, lessening the depth of fine lines. Add a spoonful to your shakes.

Top up on the sunshine vitamin. Sun damage might be the leading cause of skin ageing, but vitamin D, ironically, plays a key role in its rejuvenation. Pop a supp from October to March. And dont forget the SPF.

Plump up with collagen peptides. Research in the journal Nutrients shows this skin-boosting amino acid can reduce wrinkling and improve elasticity in 12 weeks. Vital Proteins works out at 1.40 a serving.

Inflammation ages you. In fact, Stanford scientists have even developed a test to identify your bodys inflammatory age, or iAge. One way to cool off: a separate Stanford study found that adding two or more low-sugar fermented foods or drinks to your daily diet think: kimchi, miso, tempeh and kefir has significant benefits for gut microbiome diversity, lowering vitality-sapping inflammation. Cottage cheese is another strong choice and very high in protein, too.

Research suggests an active 50-year-old can be every bit as fit as a man 30 years younger. And theres good news for the time-pressed: intensity has been found to matter more than duration. Try sprint training: a Journal Of Physiology study found that it lowered markers of inflammation (and ageing). Men in the study did three weekly sessions for six weeks, doing two or three rounds of 6-10 x 20m sprints. Run down those numbers.

Mobility matters as much as your muscle gains. Performing frequent flexibility-boosting exercises has been linked to a 24% reduced risk of functional limitation in later life, according to a Sports Medicine And Health Science review. In particular, make time to stretch out your posterior chain via toe-touches, downward dogs, lunges, etc, holding for 10 to 15 seconds. Doing so will anti-age your arteries, as well as boost your performance.

The length of our telomeres that is, the caps that protect our chromosomes is considered to be a key marker of biological ageing. And a new study from the University of Leicester has found a surprisingly simple way to hack them: quit dawdling. By studying the genetic data of more than 400,000 Brits, theyve estimated that a lifetime of brisk walking could take 16 years off a persons biological age by midlife.

Hormone therapy is on the rise among middle-aged men chasing eternal youth. But before you dabble in doping, try some of these far simpler testosterone-raising strategies:

Fill up on fats. Research has consistently linked the monounsaturated fats found in the likes of olive oil, avocado and nuts to higher testosterone. Meats not the only man food.

Go for a daily walk before work. Not only does early-morning sun exposure benefit your sleep (a lack of which tanks T levels), it also raises sex hormone levels, according to Tel Aviv scientists.

Watch your waistband. A four-point increase in your BMI can accelerate age-related testosterone decline by 10 years, particularly when fat accumulates around your middle.

The gold star in your spice rack, turmeric has been linked to everything from pain relief to immunity. A study from Syracuse University adds further bulk to this list of benefits, with animal studies showing that it can counteract age-related muscle loss, while the University of Tehran reports it might be able to reduce cellular damage, too. Knock back a juice shot at breakfast.

More than a quarter of us only visit the dentist when we have a major problem. But its worth booking in for a check-up. According to Andrew Steele, scientist and author of Ageless, better dental hygiene is one of the best ways to stave off the risk of heart disease and dementia, by eliminating the low-level gum inflammation that can accelerate age-related illness.

The number of people over 30 with high blood pressure has doubled over the past three decades and its accelerating the rate at which our brains are ageing, reports Frontiers In Aging Neuroscience. Aside from the obvious factors exercise, sleep, stress and alcohol the newest research suggests scoring your protein from a wider variety of sources can have a huge impact, dragging down your risk by two thirds. Mix up your meat with seafood, beans and eggs.

Read more from the original source:
22 Ways To Look and Feel 5 Years Younger - Men's Health